Induced expression of neuronal membrane attack complex and cell death by Alzheimer's β-amyloid peptide

Brain Research

Volumn 796, Issue 1-2, 1998, Pages 187-197

  Shen, Yong ^a   Sullivan, Traci ^a   Lee, Chi Ming ^a   Meri, Seppo ^b   Shiosaki, Kazumi ^a   Lin, Chun Wel ^a  

^a Neuroscience Department   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Amyloid peptide; Alzheimer's disease; C5b 9; CD59; Complement activation; Complement inhibitor; Cytotoxicity; MAC; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; MESSENGER RNA;

ALZHEIMER DISEASE; ARTICLE; CELL DEATH; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT INHIBITION; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NERVE CELL NECROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODIES; ANTIGENS, CD59; CELL DEATH; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; HUMANS; NEURONS; PEPTIDE FRAGMENTS; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL-LYASE; PHOSPHOLIPASE C; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0032527063     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00346-1     Document Type: Article

References (34)

1. G. Bao, R. Li, P. McGeer, Y. Shen, Neuronal localization of components of classical complement cascade in Alzheimer's disease brain. Neuroscience abstract, 1996.
2. Biedler J., Helson L., Spengler B.A. Morphology and growth, tumorigenicity and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 33:1973;2643-2652.
3. Davies A., Simmons D.L., Hale G., Harrison R.A., Tighe H., Lachmann P.J., Waldmann H. CD59, an Ly-6-like protein expressed in human lympoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Ex. Med. 170:1989;637-654.
4. Eikelenboom P., Stam F.C. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol., Berlin. 57:1982;239-242.
5. Eikelenboom P., Hack C.E., Rozemuller J.M., Stam F.C. Cerebral amyloid plaques in Alzheimer's disease but not in Scrapie-affected mice are closely associated with a local inflammatory process. Virchows Archiv. B. Cell Path. 56:1989;259.
6. Esser A.F., Thielens N.M., Zaccai G. Small angle neutron scattering studies of C8 and C9 and their interactions in solution. Biophys. J. 64:1993;743-748.
7. Gasque P., Julen N., Ischenko A., Picot C., Mauger C., Chauzy C., Ripoche J., Fontaine M. Expression of complement components of the alternative pathway by glioma cell lines. J. Immunol. 149:1992;1381-1387.
8. Gasque P., Ischenko A., Legoedec J., Mauger C., Schouft M.-T., Fontaine M. Expression of the complement classical pathway by human glioma in culture. J. Biol. Chem. 268:1993;25068-25074.
9. J. Klein, Immunology: the Science of Self-nonself Discrimination, Wiley, 1982, p. 540.
10. Kooyman D.L., Byrne G.W., McClellan S., Nielsen D., Tone M., Waldmann H., Coffman T.M., McCurry K.R., Platt J.L., Logan J.S. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science. 269:1995;89-92.
11. Johansson S. Graded action potentials generated by differentiated human neuroblastoma cells. Acta Physiol. Scand. 151:1994;331-341.
12. T. Ishii, S. Haga, F. Kametani, In: A. Pouplard-Barthelaix, J. Emile, Y. Christen (Eds.), Presence of immunoglobulins and complements in the amyloid plaques in the brain of patients with Alzheimer's disease, Immunology and Alzheimer's disease, Springer-Verlag, Berlin, 17, 1988, pp. 17-29.
13. Maenpaa A., Junnikkala S., Hakulinen J., Timonen T., Meri S. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am. J. Pathol. 148:1996;1139-1152.
14. Marchbank K.J., Morgan B.P., Van-Den Berg C.W. Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack. Immunology. 85:1995;146.
15. Master C.L., Simms G., Weinma N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 82:1985;4245-4249.
16. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:1989;341-346.
17. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:1989;516-527.
18. McGeer P.L., McGeer E.G. Complement proteins and complement inhibitors in Alzheimers disease. Res. Immunol. 143:1992;621-625.
19. McGeer P.L., Walker D.G., Akiyama H., Kawamata A.L., Guan A.L., Parker C.J., Okada N., McGeer E.G. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer's disease. Brain Res. 544:1991;315-319.
20. Meri S., Mattila P., Renkonen R. Regulation of CD59 expression on the human endothelial cell line EA. hy926. Eur. J. Immunol. 23:1993;2511-2516.
21. Meri S., Morgan B.P., Davies A., Danials R.H., Olavesen M.G., Waldmann H., Lachmann P.J. Human protein (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 71:1990;1-9.
22. Pahlman S., Mamaeva S., Meyerson G., Mattsson M.E.K., Bjelfman C., Ortoft E., Hammerling U. Human neuroblastoma cells in culture: a model for neuronal cell differentiation and function. Acta Physiol. Scand. Suppl. 592:1990;25-37.
23. Price D.L., Borchelt D.R., Walker L.C., Sisodia S.S. Toxicity of synthetic Aβ peptide and modeling of Alzheimer's disease. Neurobiol. Aging. 13:1992;623-625.
24. Rogers J., Cooper N., Webster S., Schultz J., McGeer P., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., Lieberburg I. Complement activation by β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 89:1992;10016-10020.
25. Schultz J., Schaller J., McKinley M., Bradt B., Cooper N., May P., Roger J. Enhanced cytotoxicity of amyloid β-peptide by a complement dependent mechanism. Neurosci. Lett. 175:1994;99-102.
26. Seubert P., Vigo-Pelfrey, Esch F., Lee M., Dorvey H., Sinha S., Schlossmacher, Sukanto S., Schlosmatcher M., Whaley J., Swindlehurst C., McCormack R., Wolfert R., Selkoe D., Lieberburg I., Schenk D. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature. 359:1992;325-327.
27. Shen Y., Halperin J.A., Lee C.-M. Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 671:1995;282-292.
28. Shen Y., Li R., McGeer E., McGeer P. Neuronal expression of mRNAs for complement proteins of classical pathway in Alzheimer's disease brain. Brain Res. 769:1997;391-395.
29. Smith M.D., Cribbs D.H., Tenner A.J., Shankle W.R., Dick M., Kesslak P., Cotman C.W. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol. Aging. 15:1994;609-614.
30. Stefanova I., Horejsi V., Ansotegui I.J., Knapp W., Stockinger H. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science. 254:1991;1016-1019.
31. Tshopp J., Masson D. Inhibition of the lytic activity of perforin (cytolysin) and of late complement components by proteoglycans. Mol. Immunol. 24:1987;907-913.
32. Walker D.G., Yasuhara O., Patston P.A., McGeer E.G., McGeer P.L. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 675:1995;75-82.
33. Webster S., O'Barr S., Rogers J. Enhanced aggregation and β structure of amyloid β peptide after coincubation with C1q. J. Neurosci. Res. 39:1994;448-456.
34. Zhan S.-S., Veerhuis R., Janssen I., Kamphorst W., Eikelenboom P. Immunohistochemical distribution of the inhibitors of the terminal complement complex in Alzheimer's disease. Neurodegeneration. 3:1994;111-117.